Pfizer (PFE +1.3%) and alliance partner EMD Serono (OTCPK:MKGAY) announce European Commission approval of Bavencio (avelumab), combined with Inlyta (axitinib), for the first-line treatment of adult patients with advanced renal cell carcinoma.
Last month, the advisory group CHMP adopted a positive opinion backing approval.
The FDA approved the combo for the indication in May.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.